Immune Pharmaceuticals Inc. | Ownership
Companies that own Immune Pharmaceuticals Inc.
Heights Capital Management, Inc.
265,280
0.73%
265,280
0%
06/30/2018
Credit Suisse Securities (USA) LLC (Broker)
38,399
0.11%
5,000
0%
06/30/2018
Intellectus Partners LLC
31,082
0.09%
0
0%
06/30/2018
The Vanguard Group, Inc.
600
0%
-136,241
0%
07/31/2018
Steward Partners Investment Advisory LLC
250
0%
0
0%
06/30/2018
UBS Securities LLC
5
0%
-15,643
0%
06/30/2018
Morgan Stanley & Co. LLC
3
0%
-2,746
0%
06/30/2018
RBC Dominion Securities, Inc.
0
0%
-1
0%
06/30/2018
SagePoint Financial, Inc. (Investment Management)
0
0%
-3,750
0%
06/30/2018
G1 Execution Services LLC
0
0%
-16,858
0%
06/30/2018
| Address |
550 Sylvan Avenue
Englewood Cliffs New Jersey 07632
United States
|
|
Employees
|
- |
| Website |
http://www.immunepharma.com |
| Updated |
09/14/2018 |
| Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. |
